Abstract
Biologic agents have become a core component of therapeutic strategies for many inflammatory rheumatic diseases. However, perhaps reflecting the specificity and generally high affinity of biologic agents, these therapeutics have been used by rheumatologists with less consideration of their pharmacokinetics than that of conventional synthetic DMARDs. Immunogenicity was recognized as a potential limitation to the use of biologic agents at an early stage in their development, although regulatory guidance was relatively limited and assays to measure immunogenicity were less sophisticated than today. The advent of biosimilars has sparked a renewed interest in immunogenicity that has resulted in the development of increasingly sensitive assays, an enhanced appreciation of the pharmacokinetic consequences of immunogenicity and the development of comprehensive and specific guidance from regulatory authorities. As a result, rheumatologists have a greatly improved understanding of the field in general, including the factors responsible for immunogenicity, its potential clinical consequences and the implications for everyday treatment. In some specialties, immunogenicity testing is becoming a part of routine clinical management, but definitive evidence of its cost-effectiveness in rheumatology is awaited.
Key points
-
All biologic agents are immunogenic and many pathways influence their bioavailability, including patient-specific factors, disease-specific features and genetic background.
-
The potential consequences of immunogenicity range from no clinical consequences to reduced therapeutic efficacy, infusion reactions and, rarely, serum sickness or anaphylaxis.
-
Group level pharmacokinetic models have consistently shown that anti-drug antibodies (ADAs) result in decreased serum drug concentrations and reduced efficacy.
-
The most important difference between available immunogenicity assays is the degree to which the assay is drug tolerant.
-
Coadministration of anti-proliferative and/or immunosuppressive agents such as methotrexate decreases ADA formation and maintains serum drug concentrations via various mechanisms.
-
Regular monitoring of serum drug and ADA levels has been proposed but not yet instigated into rheumatological practice, mainly owing to a lack of cost-effectiveness data.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Isaacs, J. D. et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340, 748–752 (1992).
Dörner, T. et al. The role of biosimilars in the treatment of rheumatic diseases. Ann. Rheum. Dis. 72, 322–328 (2013).
Dörner, T. et al. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 75, 974–982 (2016).
Strand, V. et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs 31, 299–316 (2017).
Kalden, J. R. & Schulze-Koops, H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat. Rev. Rheumatol. 13, 707–718 (2017).
Strand, V. et al. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs 34, 27–37 (2020).
Rup, B. et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin. Exp. Immunol. 181, 385–400 (2015).
Pyzik, M. et al. The neonatal Fc receptor (FcRn): A misnomer? Front. Immunol. 10, 1540 (2019).
Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 6, 457–462 (2002).
Montes, A. et al. Rheumatoid arthritis response to treatment across IgG1 allotype–anti-TNF incompatibility: a case-only study. Arthritis Res. Ther. 17, 63 (2015).
Ratanji, K. D., Derrick, J. P., Dearman, R. J. & Kimber, I. Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 11, 99–109 (2014).
Gill, K. L., Machavaram, K. K., Rose, R. H. & Chetty, M. Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin. Pharmacokinet. 55, 789–805 (2016).
Carmona, L., Gómez-Reino, J. J. & BIOBADASER group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res. Ther. 8, R72 (2006).
Fafá, B. P. et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADARASIL. Clin. Rheumatol. 34, 921–927 (2015).
Park, W. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72, 1605–1612 (2013).
Ungar, B. et al. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine 94, e673 (2015).
Atiqi, S., Hooijberg, F., Loeff, F. C., Rispens, T. & Wolbink, G. J. Immunogenicity of TNF-inhibitors. Front. Immunol. 11, 312 (2020).
Berkhout, L. C. et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci. Transl. Med. 11, eaat3356 (2019).
van Schie, K. A. et al. Therapeutic TNF inhibitors can differentially stabilize trimeric TNF by inhibiting monomer exchange. Sci. Rep. 6, 32747 (2016).
Berkhout, L. C. et al. The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. Rheumatology 59, 1703–1708 (2019).
Benjamin, R. J., Cobbold, S. P., Clark, M. R. & Waldmann, H. Tolerance to rat monoclonal antibodies. Implications for serotherapy. J. Exp. Med. 163, 1539–1552 (1986).
Isaacs, J. D. & Waldmann, H. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther. Immunol. 1, 303–312 (1994).
Gilliland, L. K. et al. Elimination of the immunogenicity of therapeutic antibodies. J. Immunol. 162, 3663–3671 (1999).
Jefferis, R. & Lefranc, M.-P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1, 332–338 (2009).
Webster, C. I. et al. A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors. MAbs 8, 253–263 (2016).
Rebello, P. R., Hale, G., Friend, P. J., Cobbold, S. P. & Waldmann, H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68, 1417–1420 (1999).
Schwartzman, S. et al. United States rheumatology practice-based real-world evidence of infusion reactions in rheumatoid arthritis patients treated with intravenous golimumab or infliximab: impact of prior biologic exposure and methotrexate utilization [abstract]. Ann. Rheum. Dis. 79, 994 (2020).
Wang, J. et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 26, 901–908 (2008).
Bali, D. S. et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experince. Am. J. Med. Genet. C Semin. Med. Genet. 160C, 40–49 (2012).
Garman, R. D., Munroe, K. & Richards, S. M. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase a therapy in a mouse model of Fabry disease. Clin. Exp. Immunol. 137, 496–502 (2004).
Joseph, A., Munroe, K., Housman, M., Garman, R. & Richards, S. Immune tolerance induction to enzyme-replacement therapy by co administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152, 138–146 (2008).
Joseph, A. et al. Transient low-dose methotrexate induces tolerance to murine anti-thymocyte globulin and together they promote long-term allograft survival. J. Immunol. 189, 732–743 (2012).
Gupta, S. et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 37, 366–373 (2018).
Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306, 711–720 (2011).
Baraf, H. S. et al. Tophus burden reduction with pegloticase: results from phase 3 randomised trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res. Ther. 15, R137 (2013).
Baraf, H. S., Yood, R. A., Ottery, F. D., Sundy, J. S. & Becker, M. A. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J. Clin. Rheumatol. 20, 427–432 (2014).
Keenan, R. T., Baraf, H. S. B. & LaMoreaux, B. Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase. Rheumatol. Ther. 6, 299–304 (2019).
Lipsky, P. E. et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res. Ther. 16, R60 (2014).
Hershfield, M. S. et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res. Ther. 16, R63 (2014).
Bessen, S. Y., Bessen, M. Y. & Yung, C. M. Recapture and improved outcome of pegloticase response with methotrexate — a report of two cases and review of the literature. Semin. Arthritis Rheum. 49, 56–61 (2019).
Botson, J. & Peterson, J. Pretreatment and co-administration with methotrexate improved durability of pegloticase response: a prospective, observational, proof-of-concept, case series. J. Clin. Rheumatol. https://doi.org/10.1097/RHU.0000000000001639 (2020).
Bessen, M. Y., Bessen, S. Y. & Yung, C. M. Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout — a case series. Int. J. Clin. Rheumatol. 14, 238–245 (2019).
Rainey, H., Baraf, H. S. B., Yeo, A. & Lipsky, P. Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]. Ann. Rheum. Dis. 79, 442–443 (2020).
Botson, J. et al. Pegloticase response improvement by co-treatment with methotrexate: results from the MIRROR open label clinical trial in patients with uncontrolled gout [abstract]. Ann. Rheum. Dis. 79, 446 (2020).
Masri, K., Winterling, K. & Lamoreaux, B. Leflunomide co-therapy with pegloticase in uncontrolled gout [abstract]. Ann. Rheum. Dis. 79, 454 (2020).
Kishimoto, T. K. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front. Immunol. 11, 969 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03905512 (2020).
Krishna, M. & Nadler, S. G. Immunogenicity to biotherapeutics — the role of anti-drug immune complexes. Front. Immunol. 7, 21 (2016).
van Schie, K. A. et al. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies. Ann. Rheum. Dis. 77, 1471–1479 (2018).
Lockwood, C. M., Thiru, S., Isaacs, J. D., Hale, G. & Waldmann, H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341, 1620–1622 (1993).
Bivi, N. et al. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. MAbs 11, 861–869 (2019).
Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563 (1998).
Hernandez-Florez, D. et al. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis. Rheumatol. Int. 35, 1021–1025 (2015).
Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. Ø. & Ainsworth, M. A. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post hoc analysis of a randomized controlled trial. Am. J. Gastroenterol. 109, 1055–1064 (2014).
Cohen, H. P. et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs 78, 463–478 (2018).
European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. EMA https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf (2017).
US Department of Health and Human Services. Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection. Guidance for industry. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug (2019).
Bloem, K. et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J. Immunol. Methods 418, 29–38 (2015).
Bader, L. I. et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand. J. Immunol. 86, 165–170 (2017).
Bendtzen, K. Immunogenicity of anti-TNF-α biotherapies. II. Clinical relevance of methods used for anti-drug antibody detection. Front. Immunol. 6, 109 (2015).
Cobbold, S. P., Rebello, P. R., Davies, H. F., Friend, P. J. & Clark, M. R. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J. Immunol. Methods 127, 19–24 (1990).
van Schouwenburg, P. A., Rispens, T. & Wolbink, G. J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164–172 (2013).
Liang, M. et al. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5, 655–662 (2007).
Zhong, Z. D. et al. Drug target interference in immunogenicity assays: recommendations and mitigation strategies. AAPS J. 19, 1564–1575 (2017).
Jani, M. et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis. Rheum. 67, 2011–2019 (2015).
Dirks, N. L. & Meibohm, B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 633–659 (2010).
Wolbink, G. J., Aarden, L. A. & Dijkmans, B. A. C. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21, 211–215 (2009).
Bloem, K., Hernández-Breijo, B., Martínez-Feito, A. & Rispens, T. Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context. Ther. Drug Monit. 39, 327–332 (2017).
Ternant, D., Bejan-Angoulvant, T., Passot, C., Mulleman, D. & Paintaud, G. Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis. Clin. Pharmacokinet. 54, 1107–1123 (2015).
Gunn, G. R. 3rd et al. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin. Exp. Immunol. 184, 137–146 (2016).
Benucci, M. et al. Laboratory monitoring of biological therapies in rheumatology: the role of immunogenicity. Ann. Lab. Med. 40, 101–113 (2020).
Gorovits, B. et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin. Exp. Immunol. 192, 348–365 (2018).
Freeman, K. et al. Test accuracy of drug and antibody assays for predicting response to antitumor necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis. BMJ Open 7, e014581 (2017).
Goncalves, J. et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment. Pharmacol. Ther. 48, 507–522 (2018).
Hamze, M. et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front. Immunol. 8, 500 (2017).
Mahler, S. M., Marquis, C. P., Brown, G., Roberts, A. & Hoogenboom, H. R. Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNF alpha monoclonal antibodies. Immunotechnology 3, 31–43 (1997).
[No authors listed] Nobel work that galvanized an industry. Nat Biotechnol. 36, 1023 (2018).
Harding, F. A., Stickler, M. M., Razo, J. & DuBridge, R. B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2, 256–265 (2010).
Bartelds, G. M. et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann. Rheum. Dis. 69, 817–821 (2010).
Korswagen, L. A. et al. Venous and arterial thromboembolic events in adalimumab-treated patients with anti-adalimumab antibodies: a case series and cohort study. Arthritis Rheum. 63, 877–883 (2011).
Bartelds, G. M. et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305, 1460–1468 (2011).
van Schouwenburg, P. A. et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 72, 104–109 (2013).
Vogelzang, E. H. et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis: an association with disease activity at 28 and 52 weeks follow-up. Ann. Rheum. Dis. 73, 2178–2182 (2014).
Kneepkens, E. L. et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann. Rheum. Dis. 74, 396–401 (2015).
Pouw, M. F. et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann. Rheum. Dis. 74, 513–518 (2015).
Bitoun, S. et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann. Rheum. Dis. 77, 1463–1470 (2018).
Docourau, E. et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open 6, e001047 (2020).
Humira® (adalimumab) US Package Insert (AbbVie Inc., 2008).
Burmester, G. R. et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann. Rheum. Dis. 74, 1037–1044 (2015).
Deng, Y. et al. Methotrexate reduces the clearance of adalimumab by increasing the concentration of neonatal Fc receptor in tissues. Pharm. Res. 36, 157 (2019).
Krieckaert, C. L., Nurmohamed, M. T. & Wolbink, G. J. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann. Rheum. Dis. 71, 1914–1915 (2012).
Dervieux, T., Kremer, J. M. & Weinblatt, M. E. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Ann. Rheum. Dis. 78, 1285–1286 (2019).
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493–507 (2010).
Chen, D.-Y. et al. Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment. Ann. Rheum. Dis. 74, 2261–2264 (2015).
Christen, U., Thuerkauf, R., Stevens, R. & Lesslauer, W. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum. Immunol. 60, 774–790 (1999).
Moots, R. J. et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE 12, e0175207 (2017).
Jamnitski, A. et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann. Rheum. Dis. 71, 88–91 (2012).
Jani, M. et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann. Rheum. Dis. 76, 208–213 (2017).
Berkhout, L. C. et al. The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation. Clin. Exp. Rheum. 38, 306–313 (2020).
Yusof, M. Y. M. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann. Rheum. Dis. 76, 1829–1836 (2017).
Burmester, G. R. et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 76, 1078–1085 (2017).
Actemra® (tocilizumab) US Package Insert (Genentech Inc., 2013).
Yakota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371, 998–1006 (2008).
Zuelgaray, E., Domont, F., Peiffer-Smadja, N., Saadoun, D. & Cacoub, P. Tocilizumab-induced drug reaction with eosinophilia and systemic symptoms syndrome in adult-onset Still disease: a case report. Ann. Intern. Med. 167, 141–142 (2017).
Wells, A. F. et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol. Ther. 6, 339–352 (2019).
Chiu, H.-Y., Chu, T. W., Cheng, Y.-P. & Tsai, T.-F. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS ONE 10, e0142930 (2015).
Mojtahed Poor, S. et al. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. Clin. Exp. Immunol. 196, 259–275 (2019).
Deodar, A. et al. Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. J. Rheumatol. 47, 539–547 (2020).
Karle, A., Spindeldreher, S. & Kolbinger, F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs 8, 536–550 (2016).
Muram, T. M. et al. A highly sensitive and drug-tolerant anti-drug antibody screening assay for ixekizumab using affinity capture elution. J. Invest. Dermatol. 136, 1513–1515 (2016).
Ritchlin, C. T., Merola, J. F., Gellet, A. M., Lin, C.-Y. & Muram, T. Anti-drug antibodies, efficacy, and impact of concomitant methotrexate in ixekizumab-treated patients with psoriatic arthritis [abstract]. Arthritis Rheumatol. 70, 2576 (2018).
Spindeldreher, S. et al. Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol. Ther. 8, 57–68 (2018).
Fleischmann, R. et al. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Curr. Med. Res. Opin. 30, 2139–2149 (2014).
Jamnitski, A. et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 70, 284–288 (2011).
Reynolds, A., Koenig, A. S., Bananis, E. & Singh, A. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev. Pharmacoecon. Outcomes Res. 12, 319–333 (2012).
Vincent, F. B. et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann. Rheum. Dis. 72, 165–178 (2013).
Schaeverbeke, T. et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology 55, 210–220 (2016).
Bendtzen, K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum. 63, 867–870 (2011).
Garcês, S. et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. 73, 1138–1143 (2014).
Jani, M. et al. A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology 55, 2131–2137 (2016).
l’Ami, M. J. et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann. Rheum. Dis. 77, 484–487 (2018).
Syversen, S. W. et al. Therapeutic drug monitoring compared to standard treatment of patients starting infliximab therapy: results from a multicentre randomised trial of 400 patients [abstract]. Ann. Rheum. Dis. 79, 12 (2020).
Quistrebert, J. et al. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: a European retrospective multicohort analysis. Semin. Arthritis Rheum. 48, 967–975 (2019).
Ulijn, E. et al. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD. Ann. Rheum. Dis. 79, 867–873 (2020).
National Institute for Health and Care Excellence. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis. Diagnostics guidance [DG36]. NICE https://www.nice.org.uk/guidance/dg36/chapter/1-Recommendations (2019).
National Institute for Health and Care Excellence. Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits). Diagnostics guidance [DG22]. NICE https://www.nice.org.uk/guidance/dg22/chapter/1-Recommendations (2016).
Ricciuto, A., Dhaliwal, J., Walters, T. D., Griffiths, A. M. & Church, P. C. Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis. J. Crohns Colitis. 12, 1302–1315 (2018).
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244–279 (2008).
Acknowledgements
Work in the laboratory of J.G. is supported by Fundacao para a Ciencia e Tecnologia, Portugal. Work in the laboratory of J.D.I. is supported by the National Institute for Health Research Newcastle Biomedical Research Centre, based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, UK; the Research into Inflammatory Arthritis Centre Versus Arthritis; and the Horizon 2020 Innovative Medicines Initiative 2 Rheumatherapy Cure (RT-CURE). The authors acknowledge technical support from Lisa Tait in relation to helping with the referencing in this Review.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
V.S. declares that she has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Celgene, Celltrion, Crescendo/Myriad, EMD Serono, Equillium, Galapagos, Genentech/Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, Servier, Setpoint and UCB. J.G. declares that he has received financial support for research projects from AstraZeneca, Biogen and Shire (Takeda). J.G. has also received consulting fees from Amgen, Biogen, Fresenius, Novartis, Samsung Bioepis and Sanofi. J.D.I. declares that he has received research funding from Pfizer and consulting or speaker fees from AbbVie, Amgen, Merck, Roche and UCB.
Additional information
Disclaimer
The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Peer review information
Nature Reviews Rheumatology thanks G. J. Wolbink, D. Mulleman and D. H. Yoo for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Phage display
-
A technique whereby an antibody-variable sequence is displayed on the outside of a bacteriophage that contains the DNA encoding the variable sequence, enabling the screening and selection of bacteriophages containing the genetic sequence of interest.
- Single-cell cloning
-
A technique whereby the antibody-encoding genetic material is extracted from a human B cell clone that produces the antibody of interest.
- Idiotype
-
The collection of sequences (idiotopes) that form the antigen-binding site of an antibody.
- Humanized antibodies
-
Antibodies in which the complementarity determining regions of a human antibody have been replaced with those from a mouse antibody of interest to create an antibody with the specificity of the mouse antibody in the context of a mostly human sequence.
- Chimeric antibodies
-
Antibodies in which the variable region of a mouse antibody of interest has been genetically fused with a human constant region to create an antibody that retains the specificity of the mouse antibody in the context of a human constant region.
- Fully human antibodies
-
Antibodies that contain only sequences derived from human genes.
- Cross-reactive immunological material
-
An endogenous protein in the recipient that is immunologically similar to the replacement therapy.
- Target-mediated drug disposition
-
When the binding of a drug to its target affects the pharmacokinetics of the drug.
Rights and permissions
About this article
Cite this article
Strand, V., Goncalves, J. & Isaacs, J.D. Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 17, 81–97 (2021). https://doi.org/10.1038/s41584-020-00540-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-00540-8
This article is cited by
-
A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin®) in Healthy Chinese Adults
European Journal of Drug Metabolism and Pharmacokinetics (2024)
-
Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?
Clinical Proteomics (2023)
-
25 years of biologic DMARDs in rheumatology
Nature Reviews Rheumatology (2023)
-
Sex- and gender-related differences in psoriatic arthritis
Nature Reviews Rheumatology (2022)
-
Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars
BioDrugs (2022)